mTOR Signalling Pathway-protein Expression in Post-transplant Cutaneous Squamous-cell Carcinomas Before and After Conversion to mTOR-inhibitors

被引：3

作者：

Koletsa, Triantafyllia ^{[1
]}

Petrakis, Georgios ^{[1
]}

Karayannopoulou, Georgia ^{[1
]}

Euvrard, Sylvie ^{[2
]}

Kanitakis, Jean ^{[2
,3
]}

机构：

[1] Aristotelian Univ Thessaloniki, AHEPA Hosp, Dept Pathol, Thessaloniki, Greece

[2] Ed Herriot Hosp, Dept Dermatol, Lyon, France

[3] Ed Herriot Hosp, Dept Pathol, Lyon, France

来源：

ANTICANCER RESEARCH | 2018年 / 38卷 / 06期

关键词：

mTOR signaling; pmTOR; PI3K; pAkt; squamous-cell carcinoma; skin; organ transplant recipients; immunohistochemistry; BREAST-CANCER; TRANSPLANT RECIPIENTS; MAMMALIAN TARGET; RENAL-TRANSPLANT; GROWTH-FACTOR; RAPAMYCIN INHIBITORS; SKIN CANCERS; PHASE-II; EVEROLIMUS; SIROLIMUS;

D O I：

10.21873/anticanres.12597

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: Inhibitors of the mammalian target of rapamycin (mTORis) exert immunosuppressive and antitumor effects and are used in organ-transplant recipients (OTR) as immunosuppressants able to reduce skin tumor burden. This study investigated the effects of mTORis on the expression of mTOR pathway proteins in cutaneous squamouscell carcinomas (SCC) developing in OTR, before and after switching to mTORis. Materials and Methods: An immunohistochemical study was performed on 23 SCC sections excised from OTR with post-transplant SCC, before or after switch to mTORis, with antibodies against pAkt, pmTOR and PI3K. Results: pmTOR expression was found in 8/12 SCC preswitch, and in 8/11 SCC post-switch, to mTORis. All (but 2) SCC expressed PI3K, and all SCCs expressed pAkt. Conclusion: mTORis do not significantly change the immunohistochemical expression of molecules upstream of the mTOR inhibition (pmTOR, PI3K, pAkt), in cutaneous SCC.

引用

页码：3319 / 3322

页数：4

共 30 条

[1]

Aderhold C, 2015, ANTICANCER RES, V35, P1951

[2] Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial [J].

Alberu, Josefina ;

Pascoe, Michael D. ;

Campistol, Josep M. ;

Schena, Francesco P. ;

del Carmen Rial, Maria ;

Polinsky, Martin ;

Neylan, John F. ;

Korth-Bradley, Joan ;

Goldberg-Alberts, Robert ;

Maller, Eric S. .

TRANSPLANTATION, 2011, 92 (03) :303-310

[3] Clinical activity of mammalian target of rapamycin inhibitors in solid tumors [J].

Alvarado, Yesid ;

Mita, Monica M. ;

Vemulapalli, Sushma ;

Mahalingam, Devalingam ;

Mita, Alain C. .

TARGETED ONCOLOGY, 2011, 6 (02) :69-94

[4] The TOR pathway: A target for cancer therapy [J].

Bjornsti, MA ;

Houghton, PJ .

NATURE REVIEWS CANCER, 2004, 4 (05) :335-348

[5]

Borges G, 2016, J CANC SCI THER, V8, P10

[6] Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer [J].

Campbell, S. B. ;

Walker, R. ;

Tai, S. See ;

Jiang, Q. ;

Russ, G. R. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (05) :1146-1156

[7] Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer [J].

Chan, S ;

Scheulen, ME ;

Johnston, S ;

Mross, K ;

Cardoso, F ;

Dittrich, C ;

Eiermann, W ;

Hess, D ;

Morant, R ;

Semiglazov, V ;

Borner, M ;

Salzberg, M ;

Ostapenko, V ;

Illiger, HJ ;

Behringer, D ;

Bardy-Bouxin, N ;

Boni, J ;

Kong, S ;

Cincotta, M ;

Moore, L .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5314-5322

[8] AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity [J].

Chandarlapaty, Sarat ;

Sawai, Ayana ;

Scaltriti, Maurizio ;

Rodrik-Outmezguine, Vanessa ;

Grbovic-Huezo, Olivera ;

Serra, Violeta ;

Majumder, Pradip K. ;

Baselga, Jose ;

Rosen, Neal .

CANCER CELL, 2011, 19 (01) :58-71

[9]

de Fijter JW, 2017, TRANSPLANTATION, V101, P45, DOI 10.1097/TP.0000000000001447

[10]

Dey N, 2016, PI3K MTOR CANC CANC

← 1 2 3 →